Bellicum Pharmaceuticals Inc (fka BLCM)

[Inoviorulez]

BLCM perking up, looks like new is approaching maybe soon. Hopefully Rivo-cel partnership.

[Inoviorulez]

I anticipate a partnership for rivo-cel soon for BLCM The thrive study ongoing is a market opportunity for adults in transplant worth $3 to $4 billion.

[Inoviorulez]

CEO bought 40,000 shares of BLCM the other day. Seems like partnership talk might be going well. Lots of catalysts coming up in 2nd half of 2019.

[Inoviorulez]

Very good article on BLCM

https://talkmarkets.com/content/stocks--equities/bellicum-is-worth-a-look-with-multiple-catalysts-on-the-way-in-2nd-half-of-2019?post=232773

[Inoviorulez]

New updated Presentation for BLCM

https://bellicum.gcs-web.com/static-files/f68042c1-f4d9-49dc-9e37-3a50d66bea0e

[Investor2014]

You are probably right.

[Inoviorulez]

It will head higher in the coming months. They have the MAA to file for rivo-cel pediatric blood disorders in late 2019 and then multi dose rimiducid for BPX-601 pancreatic cancer in late 2019. Based on these catalysts I believe the run is not yet over.

[ClayTrader]

* * $BLCM Video Chart 08-26-2019 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

News: $BLCM Bustling Stock- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) reached at $0.99 price level during last trade its distance from 20 days simple moving average was -16...

In case you are interested Bustling Stock- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

[Suishou]

Is this thing dead? From $30 to $.90...What's going on?

[whytestocks]

News: $BLCM Bellicum Pharmaceuticals Announces Rivo-cel(TM) Achieves Primary Endpoint in Pediatric Registrational Trial

Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial Investigational trial results support potential that haploidentical stem cell transplant may be a treatment option for a broader pediatri...

Find out more Bellicum Pharmaceuticals Announces Rivo-cel(TM) Achieves Primary Endpoint in Pediatric Registrational Trial

[ClayTrader]

* * $BLCM Video Chart 11-20-18 * *

Link to Video - click here to watch the technical chart video

[chmcnfunds]

Out for small gain @ $6.10 -- apparently too soon.

Didn't want to be in for earnings tonite.

BLCM

[chmcnfunds]

In @ $6.02 on Friday. Oversold -- now if the sector would just reverse:



BLCM

[T695]

....

[ClayTrader]

* * $BLCM Video Chart 01-31-18 * *

Link to Video - click here to watch the technical chart video

[Plegee]

Have to believe their on/off switch for CarT will be attractive for some biotech to purchase eventually. Not technologically best in class, but still appears to be a very effective way of controlling cytokine storms. The risk is others biotechs are also developing switches, some using vastly different approaches which could eventually become superior. The $8 level seems to be a good risk/reward level while waiting for a catalyst.

[greggors]

BLCM at 8 bucks now...glad I didn’t buy in the 30’s

[Jarsco]

Hold on people, I think we're going for a nice ride!

[homdance]

And told you so...,.

[homdance]

On watch here

[Cosmic Chi]

Possible but unlikely when you look at how much cash they have and how much they're burning.

Nice article summarising the progress of Bellicum and recent filings on Seeking Alpha:

https://seekingalpha.com/article/4085410-bellicum-pharmaceuticals-story-hype-hope

I wonder if this caused the SP to drop recently as investors were unsure what the filings meant (me included)...

Per Ardua Ad Astra

[G13man]

go fig , thanks
options from profit to loss ,
i will keep the nov 12.5 calls

[hentied]

Price drop due to a $150 million shelf offering filed with the SEC. Lot of potential dilution.

[G13man]

i guess the news was
1 not good enough
2 to far in to the future to profit from now

[G13man]

ouch on today drop

[martin33]

I believe it is. They are having a conference meeting with a
lot of companies tomorrow or Saturday.

[brainiac54]

is this the stock with the cd19 cancer vaccine to be announce tomorrow june 23?

[Plegee]

Very encouraging, solid gains for the last two sessions with a very red market tape. Impressive. With good volume as welll.

[Plegee]

Apologies, wrong board for drug update; got distracted. But Bakers are in with additional shares.

https://www.sec.gov/Archives/edgar/data/1358403/000114420417017097/0001144204-17-017097-index.htm

[Plegee]

Bakers in for another 166k shares per filings yesterday. Decent base action at the moment and recent fav results from Brilacidin

http://www.nasdaq.com/press-release/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-20170327-00742

[Rkmatters]

http://ir.bellicum.com/phoenix.zhtml?c=253830&ut=1485874453&p=RssLanding&cat=news&id=2240843

Get ready for commercialization. New CEO. :)

[eneels01]

https://twitter.com/loncarfunds/status/805819027876618240

[Rkmatters]

Trend continues. :)

[Rkmatters]

:)

[Rkmatters]

:)

[stocktrademan]

BLCM bullish 14.00

[Crusader]

Just hoping for a Happy

New Year, then!

[Rkmatters]

Best case scenario, that soon. :)

[Crusader]

Rk: 3rd Q sounds reasonable for designation,

September?

[Rkmatters]

Crusader,
It may end up closing below $12.50 before Friday options close. After that it will attempt the next leg up.

As for breakthrough designation, the data needs to age a bit longer, but I'm anticipating they receive that no earlier than the third quarter. December conference and this should be back to test prior highs IMHO. No looking back from there.

GLTA. :)

[Crusader]

That is a good bet, Rk.

Plus, Tom Farrell, President and CEO, was scheduled to present at the Jefferies 2016 Global Healthcare Conference. The presentation will take place on Wednesday, June 8 at 3:30 p.m. EDT in New York City.

Looks like the Jefferies conference has yet to make an impact, unless today's close counts as something.

[Rkmatters]

We're back. :)

Come on break through designation. My bet is they will receive that designation. :)

[tpizzazz24]

See IV

[favites]

Z

[Rkmatters]

AACR Late Breaking Abstract selected:

Abstract Number: LB-084

Presentation Title: Go-TCR™: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells, increasing anti-tumor efficacy

Presentation Time: Monday, Apr 18, 2016, 8:00 AM -12:00 PM
Location: Section 10
Author Block: David M. Spencer1, Tsvetelina P. Hoang1, Aaron Foster1, Tania Rodriguez1, David Torres1, An Lu1, Jeannette Crisostomo1, Lorenz Jahn2, Mirjam H.M. Heemskerk2. 1Bellicum Pharmaceuticals, Houston, TX; 2Leiden Univ Medical Center, Leiden, Netherlands

[Rkmatters]

Bellicum to Report Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call and Webcast on March 14, 2016
http://finance.yahoo.com/news/bellicum-report-fourth-quarter-full-120000398.html

Bellicum to Present at the Barclays Global Healthcare Conference
http://finance.yahoo.com/news/bellicum-present-barclays-global-healthcare-120000761.html

We should hear next week if their two clinical trial protocols have been reviewed by the NIH RAC.

[undtrdr]

An objective and fair evaluation for risk/reward RE:BPX-501 / $BLCM
blog by Timothy Sullivan
https://medium.com/@tsullivan70/bpx-501-value-proposition-explained-d54aab57b58#.2rurbx7z0

[pennystockgenius]

The phrase "Orphan Drug Designation" has a really nice ring to it

[Rkmatters]

FDA Grants Orphan Drug Designation to Bellicum’s BPX-501 for the Treatment of Immunodeficiency and GvHD Following Stem Cell Transplant
http://finance.yahoo.com/news/fda-grants-orphan-drug-designation-120000607.html

The start of the return to value. :)